Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Alpha Teknova Inc (TKNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: TKNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11
1 Year Target Price $11
| 3 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.17% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 282.17M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 5 | Beta 0.41 | 52 Weeks Range 1.23 - 10.37 | Updated Date 07/10/2025 |
52 Weeks Range 1.23 - 10.37 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.9% | Operating Margin (TTM) -50.68% |
Management Effectiveness
Return on Assets (TTM) -12.26% | Return on Equity (TTM) -28.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 285239476 | Price to Sales(TTM) 7.38 |
Enterprise Value 285239476 | Price to Sales(TTM) 7.38 | ||
Enterprise Value to Revenue 7.46 | Enterprise Value to EBITDA -6.23 | Shares Outstanding 53440800 | Shares Floating 10329574 |
Shares Outstanding 53440800 | Shares Floating 10329574 | ||
Percent Insiders 10.95 | Percent Institutions 82.17 |
Upturn AI SWOT
Alpha Teknova Inc
Company Overview
History and Background
Alpha Teknova, Inc. was founded in 1975, initially as a reagent provider for the biotechnology industry. Over time, it expanded its offerings to include custom solutions and GMP-grade products. The company has focused on innovation and quality to serve the growing needs of biopharmaceutical and cell and gene therapy companies.
Core Business Areas
- Cell Culture: Provides cell culture media, reagents, and supplements used in the development and manufacturing of biologics, cell therapies, and gene therapies.
- Genomics and Proteomics: Offers reagents, buffers, and enzymes for genomic and proteomic research and development.
- Molecular Biology: Supplies reagents for molecular biology applications, including PCR, cloning, and DNA/RNA purification.
Leadership and Structure
The leadership team consists of key executives responsible for driving the company's strategy and operations. The organizational structure is designed to support innovation, quality control, and customer service.
Top Products and Market Share
Key Offerings
- Cell Culture Media: Cell culture media for various cell types used in biologics and cell therapy production. While precise market share data is difficult to pinpoint, the competition is fierce with companies like Thermo Fisher Scientific and Cytiva (Danaher).
- GMP Buffers and Reagents: GMP-grade buffers and reagents for biopharmaceutical manufacturing, critical for ensuring product quality and regulatory compliance. No market share or revenue data is available. Competitors include Avantor and Merck.
- Custom Solutions: Custom reagent formulation and manufacturing services tailored to specific customer needs. Market share and revenue data are unavailable. Competitors include Lonza and WuXi AppTec.
Market Dynamics
Industry Overview
The life sciences reagent market is experiencing substantial growth, driven by advancements in biotechnology, biopharmaceutical development, and cell and gene therapies. The market is competitive, with many players offering similar products and services.
Positioning
Alpha Teknova positions itself as a provider of high-quality reagents and custom solutions for the life sciences industry, with a focus on GMP-grade products and customer service. It competes with larger players in the market.
Total Addressable Market (TAM)
The total addressable market for life science reagents is estimated to be in the tens of billions of dollars. Alpha Teknova's position reflects its effort to become a go-to vendor for biopharmaceutical companies
Upturn SWOT Analysis
Strengths
- High-quality products
- Custom solution capabilities
- Focus on GMP-grade manufacturing
- Strong customer relationships
Weaknesses
- Smaller scale compared to major competitors
- Limited brand recognition
- Reliance on specific market segments
Opportunities
- Expanding into new geographic markets
- Developing innovative products and services
- Acquiring complementary businesses
- Capitalizing on the growth in cell and gene therapies
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Avantor, Inc. (AVTR)
Competitive Landscape
Alpha Teknova faces strong competition from larger, more established players in the life sciences reagent market. To compete effectively, it needs to focus on innovation, customer service, and niche market segments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can only be analyzed by looking into past earnings data.
Future Projections: Future growth projections are based on analyst estimates and market conditions.
Recent Initiatives: Recent strategic initiatives would need to be researched from press releases.
Summary
Alpha Teknova is a life science reagent company that is expanding its custom solutions and GMP-grade products and services. Its strengths include custom solution capabilities and GMP-grade manufacturing. Its weaknesses include the fact that it is a smaller company compared to its competitors. The opportunities are to capitalize on growth in cell and gene therapies. The threat is intense competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Teknova Inc
Exchange NASDAQ | Headquaters Hollister, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO & Director Mr. Stephen Gunstream | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 173 | Website https://www.teknova.com |
Full time employees 173 | Website https://www.teknova.com | ||
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.